PLANO, Texas, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, will join global medtech leaders and innovators in exhibiting at the North American Neuromodulation Society (NANS) Annual Meeting in Orlando, Florida, from Jan. 30 – Feb. 1, 2025.
NANS attendees are invited to visit booth #213 to learn more about how Integer can serve as a strategic partner of choice in amplifying customers’ innovation and increasing speed to market. More specifically, Integer will showcase its latest innovations and expanded capabilities in neuromodulation to enable the next generation of miniaturized active implantable medical devices (AIMDs).
“Through miniaturization, Integer is creating the next generation of differentiated platform technologies to accelerate and de-risk OEMs’ path to market for novel implantable medical devices,” said Jim Stephens, President, Cardiac Rhythm Management & Neuromodulation. “Our broad expertise in critical implantable technologies—from batteries to fully integrated implantable pulse generator systems—uniquely positions Integer to deliver advancements in miniaturized AIMD technologies and help enable our customers’ future therapies. We look forward to discussing this and more at NANS.”
During NANS, attendees can also learn more about Integer’s Xcellion® Gen 3 Fast Charge (FC) Lithium Ion implantable battery technology. Xcellion Gen 3 FC delivers best in class battery runtime and full re-charges in as little as 30 minutes.
Learn more about Integer at www.integer.net.
About Integer®
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.
Investor Relations: | Media Relations: |
Andrew Senn | Kelly Butler |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
763.951.8312 | 469.731.6617 |
Last Trade: | US$119.96 |
Daily Change: | -1.81 -1.49 |
Daily Volume: | 316,068 |
Market Cap: | US$4.190B |
July 10, 2025 April 24, 2025 April 24, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load